Kumovis: Munich start-up with a vision for standout patient care
Kumovis got its start at the Technical University of Munich by alumni in fields ranging from medical technology to polymer engineering. The company combines its 3D printing technology with associated software to transform medical device manufacturing, and consequently help improve patient outcomes. Besides enabling functionalized and individualized medical products such as implants and surgical instruments, Kumovis offers the medtech industry a regulatory roadmap and documentation to get products to patients faster.
At the core of Kumovis’ additive manufacturing solutions is the company’s filament 3D printer for medical-grade polymers like PEEK, PEKK, PPSU or PLA: Kumovis R1 features an integrated clean room, which makes it the world’s first of its kind and ideal for healthcare applications. Using Kumovis technology, medical device companies and hospitals can tailor manufacturing to patient requirements in a resource-efficient way. It offers freedom of design with high-performance materials and has been validated by leading medical industry companies as well as hospitals.
Our vision
As Kumovis, we create leading-edge technologies to ensure outstanding patient care.
Our mission
We enable the creation of medical products that bring outstanding benefits to the healthcare sector and especially its patients. Driven by their needs, we create new technologies, develop sound processes and provide materials.
Together with our partners, we build and establish an ecosystem, that has our 3D printing knowledge and technology at its core. With everything we do, we exceed medical technology requirements and regulations.
Our history
3D printer for medical use
Kumovis GmbH gets its start by five TUM alumni, who found the company to offer a 3D printer for medical-grade polymers like PEEK.
Fall 2017Seed funding
The start-up’s round of seed funding allows for further developing its medical 3D printing system and get it ready for market.
Summer 2018ISO 9001 certification
The quality management system of Kumovis is certified according to DIN EN ISO 9001.
Summer 2019Introducing Kumovis R1
The Kumovis R1 is launched. It's the world's first 3D printer with clean room integration.
Summer 2019Series A funding
Kumovis raises Series A funding from backers including polymers specialists Solvay Ventures and Renolit.
Spring 2020Point-of-care 3D printing
Besides helping medtech companies advance their products, Kumovis installs the R1 3D printer in a hospital for the first time.
Winter 2020US subsidiary
Kumovis establishes a subsidiary in the United States to serve customers in the North American region.
Spring 2021The values we share
People
People, especially their personality and well-being, are the most valuable to us as Kumovis. We are open and respectful, and we care for each other. This is the basis of working together and building up trusting relationships – inside our team, with our partners and our customers. The motivation we have as an organization is continuously inspired by the passion of every single individual. This is what makes working together a lot of fun.
IMPACT THROUGH INNOVATION
At Kumovis, we live a culture that fosters our creativity, encourages us to try out new things and think outside of the box. We apply our strong research-based background and our mentality to think two steps ahead in order to solve complex problems.
CO-creation
Together with our interdisciplinary partners, we co-create a full solution for medical 3D printing. We believe that building up close co-operation and trustful partnerships with other experts is essential to solve today’s challenges of the healthcare sector.
RESPONSIBILITY
We are aware of the impact our work has on the well-being of patients who are treated using our technologies and services. To value this great responsibility, it is natural for us to fulfil the high requirements when building products that are applied in the medical industry.
At Kumovis, we always strive for the highest quality and reliability of our products and services. Finding the path between a high degree of innovation and meeting the requirements of the medical industry is a challenge we tackle with passion every day.
The team
Miriam
Stefan
Helge
Stefan
Katrin
Theresa
Martin
Stefan
Alexander
Dennis
Lukas
Melanie
Yannick
Juliana
Sebastian
Hans
Arnaud
Martin
Michael
Nathalie
Cemile
Our investors
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge almost 600 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital business models, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected over EUR 2.5 billion into the HTGF portfolio via more than 1,600 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies.
Investors in the public-private partnership include the Federal Ministry of Economics and Energy, KfW Capital, the Fraunhofer-Gesellschaft and 32 companies.
SOLVAY VENTURES is the Venture Capital fund of Solvay, investing in breakthrough technologies in advanced materials and formulations. Operating since 2005, Solvay Ventures currently invests out of a €80m global evergreen fund. Solvay Ventures targets early stage investment opportunities (Seed through Series B) with a focus on startups solving problems in sustainable resources, energy transition, increased wellbeing, and digital age. Beyond capital, Solvay Ventures leverages the resources at Solvay to accelerate technology and market adoption.
The RENOLIT Group is a globally active specialist for high performance polymer films, sheets and other plastic products. With more than thirty sites and sales units in over twenty countries, and with annual sales of EUR 1.059 billion in fiscal year 2019, the company with headquarters in Worms – around 70 km South of Frankfurt-am-Main – is one of the world’s leading plastics product manufacturers. More than 4,800 employees continue to further develop the knowledge and expertise gained from over seventy years of business.